[Myocardial physiopathology: the excitation-contraction block. II. Experimental and clinical aspects].
D000654:Amobarbital / Q000627:therapeutic use; D000818:Animals; D001281:Atrial Fibrillation / Q000188:drug therapy; D001692:Biological Transport; D002118:Calcium / Q000502:physiology*; D002122:Calcium Chloride / Q000627:therapeutic use; D002463:Cell Membrane Permeability; D002648:Child; D004285:Dogs; D004558:Electric Stimulation; D004562:Electrocardiography; D006168:Guinea Pigs; D006321:Heart / Q000503:physiopathology*; D006333:Heart Failure / Q000503:physiopathology*; D006801:Humans; D006996:Hypocalcemia / Q000503:physiopathology; D007223:Infant; D008564:Membrane Potentials; D009119:Muscle Contraction; D009203:Myocardial Infarction / Q000188:drug therapy; D009206:Myocardium / Q000378:metabolism; D009210:Myofibrils / Q000187:drug effects; D011817:Rabbits; D051381:Rats; D014693:Ventricular Fibrillation / Q000188:drug therapy
D000654:Amobarbital; D002122:Calcium Chloride; D002118:Calcium
Physiopathologie myocardique: le bloc excitation-contraction. II. Domaine experimental et clinique.